ClinicalTrials.gg
CompletedNCT03810742Updated Nov 18, 2023

Nanoliposomal Irinotecan (Nal-IRI, ONIVYDE®) in Combination With TAS-102 (LONSURF®) in Refractory Solid Tumors

A Phase 1 interventional study of Nanoliposomal Irinotecan in Refractory Solid Tumors, sponsored by PharmaEngine. Completed at 2 sites in Taiwan. Open to participants aged 20 Years to 70 Years. Per ClinicalTrials.gov, last updated 2023-11-18.

Sponsored by PharmaEngine · Phase 1, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
44
Allocation
Not applicable
Ages
20 Years to 70 Years
Sex
All
01

Study summary

The study is to explore the combination of nal-IRI and TAS-102, which is expected to be an effective regimen that could be applied to various cancers

Read the detailed description

Primary Objectives

  • to determine the maximum tolerated dose (MTD) of nal-IRI (ONIVYDE®) in combination with TAS-102 (LONSURF®)
  • to evaluate the toxicity profile of the combination therapy Secondary Objectives
  • to evaluate the preliminary efficacy of the combination therapy of nal-IRI (ONIVYDE®) and TAS-102 (LONSURF®)
  • to study the pharmacokinetics of the combination therapy

A phase 1 study with a classical 3 + 3 dose escalation design. The target population is patients who have pathologically confirmed malignant solid tumors with no standard treatment available.

02

Conditions studied

  • Refractory Solid Tumors
03

In context

Lead sponsor

PharmaEngine is the lead sponsor of 11 studies on the registry; 3 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
20 Years to 70 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Ages between 20 to 70 years old
  2. or cytologically confirmed malignant solid tumors which are advanced or , have failed standard treatment or have no standard treatment currently available
  3. performance status 0 or 1
  4. Normal or ECG without any findings
  5. Adequate hematologic parameters, and hepatic and renal function i. White blood cell (WBC) count 3000/μL and (ANC) 1500/μL ii. counts 100,000/μL without platelet transfusion within 14 days iii. level 10 g/dL iv. Serum total - within normal range v. Serum albumin 3.0 g/dL vi. Serum (ALT) 3 x the (ULN) vii. Serum creatinine 1.5 x ULN

Exclusion criteria

Exclusion Criteria:

  1. Received prior nal-IRI (ONIVYDE®) or TAS-102 (LONSURF®) therapy
  2. Known to any of the components of nal-IRI, other liposomal products, fluoropyrimidines or leucovorin
  3. Have liver cirrhosis with B or Child-Pugh C
  4. With active (indicated by clinical symptoms, cerebral edema, requirement, or progressive growth)
  5. With gastrointestinal disorder including hepatic disorders, bleeding, inflammation, occlusion, or diarrhea > grade 1
  6. of less than 3 months
  7. Use any anti-cancer or product within 14 days prior to the first date of study dosing
  8. History of any second in the latest 5 years except curatively treated non-melanoma skin cancer or treated cervical carcinoma in situ
  9. Uncontrolled inter-current illness including, but not limited to, ongoing or active infection requiring antibiotic treatment, symptomatic congestive heart failure, unstable angina pectoris, or cardiac arrhythmia, and psychiatric illness or social situation that would preclude study compliance
  10. Homozygous for the UGT1A1 28 allele (TA7/TA7), homozygous for UGT1A1 6 allele (A/A), or double heterozygous for both UGT1A1 28 allele (TA6/TA7) and UGT1A1 6 allele (G/A) (only for dose-finding phase)
  11. Pregnant or breastfeeding women
Terms in these criteria, in plain language(18)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Absolute neutrophil count (ANC)

The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.

It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Child-Pugh class

A score of how well the liver works in people with liver disease such as cirrhosis: class A is mild, B moderate and C severe.

Brain metastases

Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).

Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
44 participants (actual)

Study arms

  • Experimental
    Nanoliposomal Irinotecan + TAS-102

    different dosage combination by Nanoliposomal Irinotecan (nal-IRI, ONIVYDE®) in Combination with TAS-102 (LONSURF®)

    Drug: Nanoliposomal Irinotecan

Interventions

  • Nanoliposomal Irinotecan (nal-IRI, ONIVYDE®) in Combination with TAS-102 (LONSURF®)

    Also known as: TAS-102

06

What researchers measure

Primary outcomes

  1. Determination of Dose Limiting Toxicities (DLT)

    to find the Dose Limiting Toxicity (DLT) of nal-IRI (ONIVYDE®) in combination with TAS-102 (LONSURF®)

    Time frame: 12 months

  2. Evaluation of Safety profile of nal-IRI and TAS-102 - Incidence of Treatment-Emergent Adverse Events

    Incidence of Treatment-Emergent Adverse Events \[Safety\] of nal-IRI (ONIVYDE®) in combination with TAS-102 (LONSURF®) according to NCI-CTCAE version 5.0

    Time frame: 12 months

Secondary outcomes

  1. Evaluation of objective tumor response as per Response Evaluation Criteria in Solid Tumors (RECIST)

    the objective tumor rate by using RECIST v1.1

    Time frame: 24 months

  2. Pharmacokinetics study - (Cmax)

    Concentration of Peak Plasma (Cmax)

    Time frame: 6 months

  3. Pharmacokinetics study - (Tmax)

    maximum concentration of the time taken to reach the (Tmax).

    Time frame: 6 months

  4. Pharmacokinetics study - (T1/2)

    time of C max to drop in half taken (T1/2)

    Time frame: 6 months

  5. Pharmacokinetics study - (AUC0→t)

    area of the plasma concentration versus time curve (AUC0→t).

    Time frame: 6 months

  6. Pharmacokinetics study - (AUC0→∞)

    area of the plasma concentration versus under curve (AUC0→∞)

    Time frame: 6 months

  7. Pharmacokinetics study - (CL)

    rate of clearance (CL)

    Time frame: 6 months

07

Study locations

2 sites
  • China Medical University Hospital
    Taichung, Taiwan
  • National Cheng Kung University Hospital
    Tainan, Taiwan
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Mar 2019 to primary completion in May 2022, 37 months.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 21, 2018
First posted
Jan 22, 2019
StartActual
Mar 5, 2019
Primary completionActual
May 4, 2022
CompletionActual
Oct 25, 2023
Last update
Nov 18, 2023
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Nov 18, 2023, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT03810742
Lead sponsor
PharmaEngine
Responsible party
Sponsor
First posted
Jan 22, 2019
Start date
Mar 5, 2019
Primary completion
May 4, 2022
Completion
Oct 25, 2023
Last update
Nov 18, 2023

Study contacts

Chia-Chi Lin, MD
principal investigator · National Taiwan University Hospital, Taipei, Taiwan

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Nov 2023. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Irinotecan sucrosofate

Start the discussion